A phase 1/2 trial of CAN016 in advanced solid tumours, run by Canwell Biotech Limited, now recruiting.
CW-301 FIH Study of CAN016 is a phase 1/2 interventional study registered as NCT07664150 by Canwell Biotech Limited, with 90 participants planned, started 2026-06-18 and due to reach its primary completion in 2028-12-30. Interventions recorded: CAN016.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.